Stephen Graziano is an Oncology physician affiliated with SUNY Upstate Medical University. OpenAlex indexes 152 publications with 7,584 citations (h-index 44); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
750 E Adams St
Regional Oncology Center
Syracuse, NY 132102306
Telephone
315-464-8200Registry record last updated 9 Jun 2010.
Clinical trials
- Biomarkers in Predicting Response in Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy
Sponsor: Alliance for Clinical Trials in Oncology
- Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer
Sponsor: Gynecologic Oncology Group
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20251 payment
- Incyte CorporationProgram year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
34%Phenothiazine12.7%Prochlorperazine Maleate100%Part D≥23 patientsGabapentinoids11.3%Gabapentin100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
25%Serotonin-3 Receptor Antagonist17.5%Ondansetron Hcl100%Part D≥24 patientsCorticosteroid7.5%Prednisone100%Part D≥13 patientsHormonal (systemic)
18.9%l-Thyroxine18.9%Levothyroxine Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 1990–2002 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer
Journal of Clinical Oncology
2018
Similar KOLs
Other experts from the same institution or the same specialty.
Jeffrey Ross, MD
SUNY Upstate Medical University
Andras Perl, MD
SUNY Upstate Medical University
Ruth Weinstock, MD
SUNY Upstate Medical University
Srikanth Yandrapalli, MD
SUNY Upstate Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”